US based Johnson & Johnson filed for arbitration to terminate a marketing agreement over Remicade (Infliximab) and Simponi (Golimumab) with Schering-Plough Corp, after signed acquisition with rival Merck & Co.

Indianapolis-based drug maker Eli Lilly & Co. sued Cobalt Laboratories Inc., Impax Laboratories Inc., Sandoz Inc. and Wockhardt Ltd., after the companies filed abbreviated new drug applications to sell duloxetine, the active ingredient of the anti-depressant Cymbalta. The blockbuster drug patent expires in 2013.

Federal and state prosecutors are investigating whether Merck & Co and Schering-Plough Corp improperly promoted the cholesterol-fighting medication Vytorin, adding to the government probes and private lawsuits involving the jointly marketed drug.

Canadian drugmaker Biovail Corp reported it is being sued by investors who allege it made misleading statements during the approval process for the depression drug Aplenzin.

According to documents submitted in a U.S. consolidated lawsuit by health insurers and consumers against Pfizer Inc., the company suppressed information from medical studies that did not support the use of its epilepsy drug Neurontin as a drug for other conditions besides epilepsy. Plaintiffs are seeking $ 4.9 billion dollars in damages for alleged civil fraud.

Indianapolis-based Eli Lilly & Co. has filed a lawsuit against Israel´s generic-drug maker Teva Pharmaceutical Industries Ltd., alleging infringement of two U.S. patents used for its cancer drug Gemzar (gemcitabine).

World’s largest generics maker Teva Pharmaceutical Ind Ltd announced is has filed a lawsuit against Switzerland´s Novartis AG and U.S. drugmaker Momenta Pharmaceuticals Inc. for patent infringement of its multiple sclerosis treatment Copaxone. Teva claims the patents are valid and enforceable through 2014 and 2015. Further details.

Germany's Bayer AG is suing Novartis AG's Sandoz unit to prevent it from selling a copy of the Yaz birth-control pill in the U.S. Bayer is seeking to block approval of the generic version until two patents on the drug expire in 2014.

Swiss giant drugmaker Novartis announced it has filed a lawsuit in the U.S. against Israeli generics firm Teva, over patents for Zometa and Reclast, the company´s bone disease treatment drugs. Further details.

Barr Pharmaceuticals Inc. announced it is being sued by Amgen Inc. over a challenge to the biotechnology company´s hyperparathyroidism drug Sensipar. Further details.

Merck & Co said that over 97 percent of eligible U.S. claimants have accepted to enter into a record $4.85 billion Vioxx settlement, one of the largest civil settlements ever

A 55-year-old former Wall Street banker is suing drugmakers involved with Parkinson’s disease drug Mirapex over his $3 million gambling losses

The widow of a man who allegedly committed suicide after using Pfizer Inc.´s smoking-cessation treatment Chantix, filed a lawsuit against the world number one drugmaker, claiming Pfizer failed to properly warn of the pill´s psychiatric side effects. Lawyer believes this suit will kick off many more Chantix litigations. Further details.

A 55-year-old former Wall Street banker is suing drugmakers involved with Parkinson’s disease drug Mirapex over his $3 million gambling losses

MedImmune Inc has settled its five-year lawsuit against Genentech Inc over the Synagis patent, for which MedImmune was paying royalties, reported a U.S. district court.

London-based AstraZeneca is being sued by Arkansas over questionable Seroquel marketing practices and false ads claims. According to Arkansas Attorney General Dustin McDaniel, the Anglo-Swedish drugmaker claimed its antipsychotic pill was safer than cheaper versions and failed to warn of its risks

Israel’s generic drugs giant Teva is suing AstraZeneca, seeking a declaratory judgment on additional Nexium patents. The Anglo-Swedish company had sued Teva for patent infringement over some of its blockbuster ulcer pill patents, and now Teva is asking the court to demand AstraZeneca to either sue or declare the remaining patents invalid or non-infringed

Germany’s Bayer has filed a lawsuit against French giant Schering-Plough for an unspecified amount of payments made under a 2004 U.S. drug distribution contract for patents, a report published in The News Journal stated.